ArticleJournal of family medicine and primary care2025
Cutaneous mucormycosis: Unveiling rare manifestations.
Article in Journal of family medicine and primary care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tropical infectious diseases and skin manifestations: a diagnostic framework.Current opinion in infectious diseases · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucormycosis is a rare but life-threatening fungal infection caused by Mucorales, with high morbidity and mortality rates, especially among immunocompromised individuals. We report six cases of rare manifestations of cutaneous mucormycosis. To describe rare manifestations of cutaneous mucormycosis, highlighting the importance of prompt recognition and treatment to improve patient outcomes. Retrospective review of medical records from 2021 to 2023. This case series presents six patients with rare manifestations of cutaneous mucormycosis. The patients' ages ranged from 25 to 60 years, with an equal male-to-female ratio. Comorbidities included diabetes, HIV/AIDS, chronic kidney disease, connective tissue disorder, leukemia, and systemic lupus erythematosus (SLE). All six patients (100%) presented with cutaneous mucormycosis, with varying clinical manifestations, including necrotizing fasciitis of the scalp (16.7%), cutaneous lesions of the buttock (16.7%), fungal keratitis and endophthalmitis with periorbital cutaneous lesions (16.7%), mucormycotic abdominal wall lesions (16.7%), mucormycotic osteomyelitis of the mandible with overlying skin blackening (16.7%), and cerebral vasculitis with scalp skin lesions (16.7%). The most common clinical features are fever (83.3%), pain (66.7%), and swelling (50%). Laboratory findings include elevated WBC count (83.3%), positive fungal culture (100%), and histopathology (83.3%). Treatment consisted of surgical debridement (83.3%), antifungal therapy with amphotericin B (100%), and supportive care. Outcomes were favorable, with one patient achieving complete recovery (16.7%), four showing improvement (66.7%), and one experiencing disease stabilization (16.7%). Notably, no mortality was reported. Cutaneous mucormycosis can manifest in diverse ways. Early recognition and treatment are crucial to prevent morbidity and mortality associated with this rare and devastating fungal infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.